Cabozantinib s-malate by Exelixis for Gastric Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cabozantinib s-malate overview

Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a s-malate salt form of cabozantinib. It is formulated as hard gelatin capsules for oral route of administration. Cometriq is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Cabozantinib is under development for the treatment of metastatic cervical cancer, metastatic castration-resistant prostate cancer (mCRPC), clear cell renal cell carcinoma, advanced or metastatic urothelial cancer, carcinoid tumor, gastroesophageal adenocarcinoma, metastatic melanoma, thyroid cancer, neuroendocrine gastroenteropancreatic tumors, hepatocellular carcinoma, pheochromocytoma, paraganglioma (glomus jugulare tumor), pancreatic neuroendocrine tumor, endometrial cancer, rhabdomyosarcoma, non-rhabdomyosarcoma, Wilms’ tumor (nephroblastoma), Ewing sarcoma, osteosarcoma, soft tissue sarcoma, recurrent head and neck cancer squamous cell carcinoma, squamous cell carcinoma, metastatic colorectal cancer, colorectal cancer, gastric cancer, plexiform neurofibroma, penile cancer, adenocarcinoma of the gastroesophageal junction, advanced melanoma, non-small cell lung cancer, esophageal cancer, small cell lung cancer (SCLC), recurrent or progressive meningioma, papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) and triple-negative breast cancer (TNBC).

The drug candidate was also under development for the treatment of relapsed/refractory acute myeloid leukemia, anaplastic thyroid cancer, astrocytoma, glioblastoma multiforme, renal failure, Merkel cell carcinoma, metastatic renal cell carcinoma, urethral cancer, ureter cancer, peritoneal cancer, pancreatic tumor, metastatic adenocarcinoma of the pancreas, bladder cancer, metastatic uveal melanoma, epithelial ovarian cancer, fallopian tube cancer, hormone-receptor-positive breast cancer with bone metastases, relapsed/refractory multiple myeloma, papillary renal cell carcinoma and gastroesophageal (GE) junction carcinomas.

Exelixis overview

Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors and CBX-12 for advanced metastatic refractory solid tumors. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.

For a complete picture of Cabozantinib s-malate’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.